Zoetis Inc. (ZTS) Financials
ZTS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 14.3 billion | 9.3 billion |
2023-09-30 | 14.1 billion | 9.0 billion |
2023-06-30 | 13.7 billion | 9.1 billion |
2023-03-31 | 13.8 billion | 9.3 billion |
ZTS Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 699.0 million | 17.0 million |
2023-09-30 | 579.0 million | 17.0 million |
2023-06-30 | 17.0 million | 17.0 million |
2023-03-31 | 326.0 million | 9.0 million |
ZTS Net Income
Date | Net Income |
---|---|
2023-12-31 | 525.0 million |
2023-09-30 | 596.0 million |
2023-06-30 | 670.0 million |
2023-03-31 | 551.0 million |
ZTS Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 2.0 billion | - | 188.0 million |
2023-09-30 | 1.8 billion | 6.6 billion | 191.0 million |
2023-06-30 | 1.7 billion | 6.6 billion | 188.0 million |
2023-03-31 | 2.1 billion | 6.6 billion | 180.0 million |
ZTS Shares Outstanding
ZTS Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 198.0 million | 174.0 million | 565.0 million | - |
2023-09-30 | 145.0 million | 152.0 million | 525.0 million | - |
2023-06-30 | 166.0 million | 146.0 million | 556.0 million | - |
2023-03-31 | 223.0 million | 142.0 million | 505.0 million | - |
ZTS Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 2.2 billion | 765.0 million |
2023-09-30 | 2.2 billion | 638.0 million |
2023-06-30 | 2.2 billion | 607.0 million |
2023-03-31 | 2.0 billion | 588.0 million |
ZTS
List: Contenders
Price: $150.88
Dividend Yield: 0.01%
Forward Dividend Yield: 1.16%
Payout Ratio: 35.19%
Dividend Per Share: 1.73 USD
Earnings Per Share: 5.07 USD
P/E Ratio: 38.08
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 1.6 million
Ebitda: 543.0 millionMarket Capitalization: 68.5 billion
Average Dividend Frequency: 4
Years Paying Dividends: 12
DGR3: 18.80%
DGR5: 19.52%
DGR10: 16.63%